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2 
Introduction 
  
 Cardiovascular diseases (CVD) cause of more than 4 million deaths in Europe and over 
1.9 million deaths in the European Union each year. Since decades, it is the leading cause of 
morbidity and mortality statistics in the developed part of the world. According to 
epidemiological studies, risk factors such as smoking, diabetes, hyperlipidemia, nutrition 
factors and age dispose changes in the cardiovascular system that in time may lead to CVD. 
Endothelial dysfunction is a corner-stone of cardiovascular diseases associated to 
hypercholesterolemia, hypertension, diabetes mellitus, ischemia reperfusion injury and sepsis. 
Growing evidence indicates, that in vivo formation of free radicals in the vascular wall plays a 
pivotal role in the development of endothelial dysfunction, that contributes to initiation and 
progression of these diseases. The vascular system, especially the endothelium itself is very 
sensitive to oxidative stress. Under normal circumstances in healthy cells, a balance exists 
between the formation of reactive oxygen species (ROS) and their effective elimination by 
protective antioxidant mechanisms. During oxidative stress, the disruption of this balance 
favours ROS production thus impairing cellular functions on multiple levels via a wide range 
of processes: oxidizing proteins and lipids, the oxidative damage of the DNA may lead to 
apoptosis, autophagy or in higher concentrations causing necrosis of the cell. Reactive oxygen 
species include superoxide (O2-.), hydrogen peroxide (H2O2), hypochlorite (OCl-), hydroxyl 
ions (.OH) and peroxynitrite (ONOO-) which is one of the most harmful oxidant species from 
the reaction of superoxide and nitric oxide. The superoxide anion scavenges nitric oxide (NO.) 
and forms peroxynitrite, which in turn induces tyrosine nitration and deleterious protein 
changes, triggering proinflammatory signals and inhibiting endothelial repair. 
Impaired endothelial function is correlated with cardiovascular diseases, therefore therapeutic 
strategies aimed at limiting vascular oxidative stress and improving endothelial function, may 
have clinical benefits. It has been widely discussed, that NO - cyclic guanosine 
monophosphate (cGMP) – protein kinase G pathway regulates vascular tone, platelet 
aggregation, cellular growth and proliferation, and extracellular matrix deposition. Their 
dysfunction is therefore the target of many therapeutic drugs derived from NO/cGMP 
stimulators and blockers. Intracellular cGMP accumulation has been shown to reduce tissue 
injury in conditions associated with increased free radical release and oxidative stress. As 
novel therapeutic approach, new classes of drugs are aimed to modulate the NO.- sGC- cGMP 
pathway. 
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Soluble guanylate cyclase (sGC) is the downstream molecule in the NO/cGMP signaling 
pathway, and is responsible for the conversion of GTP to the messenger molecule cGMP. 
ROS affect the heme-containing NO. receptor of sGC by both decreasing its expression and 
by causing the dissociation of the heme. Oxidation thus potentially impairs NO-induced 
activation and destines the enzyme to degradation. As a result, NO. donors and other 
pharmacological agents that protect vascular function through NO-dependent activation of 
sGC may not be as beneficial in the setting of oxidative stress or I/R injury. In preclinical 
studies the novel heme-independent sGC activator cinaciguat has been shown to bypass the 
impaired NO-sGC-cGMP pathway by activation of the oxidized (Fe3+)/heme-free forms of 
sGC and to preferentially dilate the diseased versus non-diseased vasculature. In a phase I 
clinical trial in healthy human participants, intravenously administered cinaciguat had a 
favourable safety profile and was well tolerated. 
The availability of the messenger cGMP is regulated by not only its synthesis, but through its 
degradation by phosphodiestherases, which are thereby also cornerstone regulators of the 
pathway. From eleven currently known members of the phosphodiestherase family more than 
seven may interact with cGMP, but in the cardiovascular system (including vessel wall) the 
cGMP selective phosphodiestherase-5 (PDE-5) is responsible dominantly for its metabolism. 
cGMP facilitates its own degradation by negative feed-back through the up-regulation and 
marked activation of PDE-5. In cardiovascular diseases due to oxidative stress significantly 
increased PDE-5 expression was detected to accelerate cGMP degradation. Vardenafil is a 
well-known selective PDE-5 inhibitor that was recently shown to have beneficial effects 
against myocardial I/R injury after preconditioning-like treatment in rabbits and to have 
advantageous protective effect on vascular endothelium. 
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Objectives 
 
Based upon the described mechanisms how oxidative stress leads to endothelial and vascular 
dysfunction, the present studies investigate whether increased cGMP levels contribute to the 
protection of vascular function and structure against acute oxidative stress. 
 
1. The aims of the first in vitro model of vascular oxidative stress induced by 
peroxynitrite incubation was: 
• the investigation of vascular dysfunction and the contribution of decreased 
cGMP level to it after an acute oxidative stress; 
• testing the effect of the soluble guanylate cyclase activator cinaciguat on 
vascular dysfunction induced by peroxynitrite and underlying cellular and 
molecular changes in the vessel wall; 
 
2. The aim of the second model of vascular oxidative stress induced by the model of in 
vitro ischemia and reperfusion was: 
• the investigation of I/R injury on vascular function, structure and cGMP levels; 
• testing the effect of the selective phosphodiesterase -5 inhibitor vardenafil-
maintained cGMP levels on vascular dysfunction induced by in vitro I/R 
injury; 
 
As a summary, the main goal of the studies was to establish novel potent therapeutic 
strategies facilitating the NO-sGC-cGMP pathway for ameliorating the endothelial and 
vascular dysfunction associated with acute oxidative stress. 
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Methods 
 
I. Experimental models 
1. In vitro model of vascular dysfunction induced by peroxynitrite exposure 
Thoracic aortic rings were isolated from male Sprague-Dawley rats. In organ bath 
experiments for isometric tension the effect of in vitro peroxynitrite exposure on 
vasoconstriction, endothelium-dependent and independent vasorelaxation was measured as 
described detailed below. Endothelial injury was induced by incubating the isolated aortic 
rings in peroxynitrite (200 µmol/L) for 30 minutes. Rats of the treated group received orally 
two times sGC activator cinaciguat (10 mg/kg). 
 
2. In vitro model of vascular dysfunction induced by long term cold preservation, 
reoxygenation and hypochlorite exposure 
Thoracic aortic rings were isolated from rats and incubated in cold hypoxic saline for 24 
hours. In organ bath experiments for isometric tension the effect of in vitro hypochlorite 
exposure on vasoconstriction, endothelium-dependent and independent vasorelaxation was 
measured as described below. Endothelial injury was induced by reoxygenation and 
incubating the isolated aortic rings in hypochlorite (200 µmol/L) for 30 minutes. Cold 
hypoxic solution of the treated group was enriched with different concentrations the of PDE-5 
inhibitor vardenafil (10-12 mol/L, 10-11 mol/L, 10-10 mol/L, 10-9 mol/L). 
 
II. In vitro organ bath experiments 
Thoracic aorta was carefully excised, cleaned from connective tissue and cut transversely 
into 4 mm wide rings. Isolated aortic rings were mounted on stainless steel hooks in 
individual organ baths, containing 25 ml of Krebs–Henseleit solution at 37 °C and aerated 
with 95% O2 and 5% CO2. Isometric contractions were recorded using isometric force 
transducers of a myograph. The aortic rings were placed under a resting tension of 2g and 
equilibrated for 60 minutes. Krebs–Henseleit solution was changed in every 30 minutes. At 
the beginning of each experiment, the maximal contraction forces in response to potassium 
chloride (KCl, 80 mmol/L) were determined and then aortic rings were washed until the 
resting tension was obtained again. Afterwards, to simulate free radical burst which occurs 
usually in vivo during reperfusion, determined by the experimental setup, 200 µmol/L 
hypochlorite or 200 µmol/L peroxynitrite was added to the baths for 30 minutes, then washed 
out. Aortic preparations were preconstricted with α-adrenergic receptor agonist phenylephrine 
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(PE, 10−6 mol/L) until stable plateau was reached, and relaxation responses were examined by 
adding cumulative concentrations of endothelium-dependent dilator acetylcholine (ACh, 
10−9–10−4 mol/L). For testing relaxing response of smooth muscle cells, a direct nitric oxide 
donor, sodium nitroprusside (SNP, 10−10–10−5 mol/L) was used. Contraction responses are 
expressed in gramm, relaxational responses are expressed in percentage of phenylephrine 
contractions.  
 
III. Histopathological processing 
1. Immunohistochemical and TUNEL (terminal deoxynucleotidyl transferase-
mediated dUDP nick end-labeling) stainings 
Aortic segments from each experimental group were fixed in paraformaldehyde solution 
(4%) and embedded in paraffin. 3-µm-thick sections cut by microtome were placed on 
adhesive slides. According to previously described methods, we performed 
immonohistochemical staining for the detection of nitrotyrosine (marker of peroxynitrite-
mediated damage) and for the detection of cyclic GMP content. TUNEL assay was performed 
for detection of DNA strand breaks (free 3'-OH DNA ends). 
 
2. Quantification of immunostainings and TUNEL assay 
Semiquantitative histomorphological assessment was performed on all of the stained 
specimens of cinaciguat and vardenafil projects in a blinded fashion. The results were 
expressed with a scoring system in regard to the intensity and the ratio of the stained cells. For 
the assessment of TUNEL-labeled cells TUNEL positive and negative cell nuclei were 
counted and the TUNEL positive cell nuclei were calculated as percentage of total cell 
number. 
 
IV. Quantitative Real-Time Polymerase Chain Reaction (PCR) 
From the aortic rings total RNA was isolated, transcribed, and quantitative real-time PCR 
was preformed for the detection of mRNA expression of ET-1, Caspase-3, BAX, Bcl-2, 
eNOS, iNOS. Efficiency of the PCR reaction was confirmed with standard curve analysis. 
Every sample was quantified in duplicate, normalized to glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) expression. 
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V. Western-blot analysis 
Proteins expression of p17 caspase-3 fragment, Bax and Bcl-2 was determinated by 
conventional Western-blot method. Target protein densities were normalized to housekeeping 
GAPDH densities of the same samples, respectively. 
 
VI. Statistical Analysis 
Data were tested for normal distribution (Shapiro-Wilk) and where met the requirements 
for parametric analysis, means were tested by one-way ANOVA followed by Student's 
unpaired t-test with Bonferoni’s correction test. For the analysis of PCR results Kruskal-
Wallis one-way analysis of variance with Dunn's post hoc test was used. A p value <0.05 was 
considered statistically significant. 
 
VII. Preparation of chemical reagents 
Cinaciguat (BAY 58-2667) was dissolved in 1% methylcellulose solution vehicle, while 
peroxynitrite was diluted with 4.7% NaOH. Vardenafil, phenylephrine, acetylcholine and 
sodium nitroprusside were diluted in physiologic salin. Sodium-hypochlorite solution was 
diluted with distilled water. 
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Results 
 
I. Vascular injury induced by peroxynitrite in vitro - effects of cinaciguat 
1. Vascular dysfunction of aortic rings 
 Exposure of aortic rings to the reactive oxidant peroxynitrite significantly attenuated the 
maximal relaxation response to the acetylcholine-induced, endothelium-dependent, NO-
mediated vasorelaxation. In harmony with our expectations, pre-treatment of rats with 
cinaciguat significantly improved the endothelium-dependent relaxation after exposure of 
aortic rings to peroxynitrite. Maximal relaxations to endothelium-independent vasodilator 
sodium nitroprusside did not differ significantly among the different experimental groups 
(Table I). 
 
 Control Peroxynitrite Cinaciguat+ 
Peroxynitrite 
Cinaciguat 
Rmax to ACh (%) 93.2 ± 2.0 44.5 ± 5.9* 67.1 ± 3.5*,# 93.9 ± 1.1# 
pD2 to ACh 7.6 ± 0.1 6.6 ± 0.2* 7.0 ± 0.1 7.9 ± 0.1# 
Pmax to SNP (%) 100.1 ± 0.2 100.2 ± 0.3 100.2 ± 0.2 101.6 ± 0.2 
pD2 to SNP 8.8 ± 0.2 8.2 ± 0.1* 8.2 ± 0.1* 9.1 ± 0.3# 
PE (% of KCl) 73 ± 5 114 ± 3* 108 ± 5* 78 ± 5# 
Table I: Values of maximal relaxation (Rmax, %) and pD2 (affinity) to the vasorelaxant 
actions of acetylcholine (ACh) and sodium nitroprusside (SNP), and contraction values 
induced by phenylephrine (PE % of KCl) in percentage of the contraction induced by 0.1 
mol/L potassium-chloride caused depolarization in rat thoracic aortic rings. 
Values represent mean ± S.E.M. of 12-15 experiments. 
*p < 0.05 versus control; # p < 0.05 versus peroxynitrite group; 
 
 
 2. Immunohistochemistry and TUNEL 
 A large increase in the intensity of nitrotyrosine staining was detected in the 
peroxynitrite-incubated rings compared to the control segments which was reduced after 
cinaciguat pretreatment, as evidenced by decreased brown staining (Control: 3.8±0.4 vs. 
ONOO-: 6.4±0.4, p<0.05; ONOO- vs. Cinaciguat+ONOO-: 4.4±0.3; p<0.05). 
Though we detected no significant change after peroxynitrite exposure in the aortic rings, pre-
treatment of rats with cinaciguat, resulted in a significantly higher score of cGMP compared 
to the peroxynitrite-incubated segments (ONOO-: 5.9±0.7; vs. Cinaciguatt+ONOO-: 7.9±0.6; 
p<0.05; Control: 7.2±0.6; Cinaciguat: 7.7±0.8). 
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Increased density of TUNEL-positive nuclei was observed in the wall of peroxynitrite-
exposed aortic rings indicating DNA-fragmentation. Pretreatment of rats with cinaciguat 
significantly decreased peroxynitrite-induced DNA strand breaks (Control: 35±2 vs. ONOO-: 
49±3; p<0.05; ONOO- vs. Cinaciguat+ONOO-: 34±3; p<0.05). 
 
3. Cinaciguat regulates gene expression 
 Exposure of aortic rings to peroxynitrite significantly up-regulated the expression of ET-
1, BAX and Caspase-3 mRNA, compared to native control rings. Cinaciguat pre-treatment 
significantly moderated this up-regulation caused by peroxynitrite compared to the ONOO- 
group. The significant reduction of Bcl-2 mRNA expression in the peroxynitrite exposed rings 
was totally overturned by cinaciguat treatment. The mRNA expression of eNOS was 
significantly suppressed by peroxynitrite exposure. Peroxynitrite exposed rings after 
cinaciguat treatment did not show significant difference compared to control group. In the 
expression of inducible NO. synthase mRNA no significant difference was detected among 
the groups. 
 
4. Effect of cinaciguat on cleaved caspase-3 level, Bax and Bcl-2 protein expression 
 Densitometric analysis of the bands revealed a 2-fold increase of caspase-3 p17 cleavage 
protein presence and a 5-fold increase of BAX protein presence in peroxynitrite-exposed 
rings. Cincaiguat treatment significantly decreased the presence of these pro-apoptotic 
proteins in rings exposed to peroxynitrite. Cinaciguat treatment alone caused no significant 
changes in protein levels. Expression of the anti-apoptotic Bcl-2 protein was significantly 
decreased in the peroxynitrite exposed group compared to control, while the cinaciguat 
resulted in maintained Bcl-2 levels in both cinaciguat treated groups. 
 
II. Vascular dysfunction induced by cold preservation, in vitro reoxygenation and 
hypochlorite - effects of vardenafil 
 1. Vascular dysfunction of aortic rings 
 Aortic segments exposed to 24 hours long cold ischemic storage followed by 
hypochlorite (200 µmol/l) incubation showed significantly attenuated maximal relaxation to 
the acetylcholine induced endothelium-dependent, NO. mediated vasorelaxation, as compared 
to control group. Supplementation of the conservation solution with 10-11 mol/L Vardenafil 
significantly improved the acetylcholine induced vasorelaxation after the exposure of rings to 
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hypochlorite, compared to saline group. There was no statistical difference among the 
vardenafil treated groups. In contrast to acetylcholine, endothelium-independent 
vasorelaxation of the aortic rings to sodium-nitroprusside showed no significant difference in 
maximal relaxation among the experimental groups (Table II). 
 
 Control Saline 
Vardenafil 
(10-12 M) 
Vardenafil 
(10-11 M) 
Vardenafil 
(10-10 M) 
Vardenafil 
(10-9 M) 
Rmax to ACh (%) 97.9 ± 0.56 48.3 ± 5.6* 64.2 ± 3.3* 74.8 ± 3.5*,# 68.3 ± 4.5* 61.0 ± 4.5* 
pD2 to ACh 7.6 ± 0.09 6.4 ± 0.1* 6.7 ± 0.1* 6.9 ± 0.1*,# 6.83 ± 0.1* 6.7 ± 0.1* 
Rmax to SNP (%) 99.9 ± 0.02 99.8 ± 0.1 99.5 ± 0.4 99.9 ± 0.1 99.9 ± 0.1 99.8 ± 0.1 
pD2 to SNP 8.3 ± 0.07 8.2 ± 0.1 8.3 ± 0.1 8.8 ± 0.2* 8.4 ± 0.1 8.2 ± 0.1 
PE (% of KCl) 75.5 ± 2,75 121.2 ± 1.9* 117.3 ± 5.8* 122.1 ± 4.3* 110.4 ± 4.9* 124.9 ± 7.9* 
Table II: Values of maximal relaxation (Rmax, %) and pD2 (affinity) to the endothelium-
dependent vasorelaxant action of acetylcholine (ACh) and sodium nitroprusside (SNP), and 
contraction induced by phenylephrine (PE % of KCl) in percentage of the contraction induced 
by 0.1 mol/L potassium-chloride caused depolarization in rat thoracic aortic rings.Values 
represent mean ± S.E.M. of 15-20 experiments. 
*p < 0.05 versus Control; # p < 0.05 versus Saline group; 
 
 
 2. Immunohistochemistry and TUNEL 
 Cold ischemic conservation for 24 hours followed by reoxygenation and 30 minutes 
hypochlorite incubation led to significantly lower cGMP immunreactivity in the saline group, 
compared to the control group. Vardenafil-supplementation led to significantly higher score 
of cGMP staining, compared with the saline group. 
Cold ischemic conservation, reoxygenation and hypochlorite incubation led to significantly 
increased density of TUNEL-positive nuclei in the aortic segments, compared to control rings 
(control: 10±6 vs. saline: 72±4; p>0.05). This indicates oxidative stress caused DNA-
fragmentation in the aortic wall. Vardenafil-supplementation significantly decreased DNA 
strand breaks (saline vs. vardenafil 10-11: 14±5; p<0.05). 
 
 3. Vardenafil regulates aortic gene expression 
 Exposure of aortic rings to 24 hours cold ischemic conservation followed by 30 minutes 
hypochlorite incubation significantly up-regulated the expression of ET-1, BAX and Caspase-
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3 mRNA, compared to native control rings. These changes were significantly moderated by 
vardenafil supplementation of preservation solution. Long ischemic storage and hypochlorite 
exposure caused a significant down-regulation of Bcl-2 mRNA expression, which was 
improved by vardenafil. Vardenafil supplementation of the storage solution did not influence 
the mRNA level of endothelial and inducible nitric oxide synthases. 
 
4. Effect of vardenafil on cleaved caspase-3 level, Bax and Bcl-2 protein expression 
Densitometric analysis of caspase-3 p17 cleavage and Bax bands after 24 hours of cold 
storage and hypochlorite exposure showed a significant increase in saline group compared to 
control group. This up-regulation of protein level was significantly moderated by vardenafil 
supplementation. Expression of the anti-apoptotic Bcl-2 protein was significantly decreased in 
saline group compared to control, while the supplementation of vardenafil maintained Bcl-2 
levels on the level of controls. 
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Conclusions 
 
The main results of this dissertation shall be resumed in 2 main theses: 
• Acute oxidative stress such as preoxynitrite load or reperfusion injury leads to 
decreased intracellular cGMP bioavailability in the vascular wall and consequently to 
vascular dysfunction. This phenomenon is accompanied by further molecular changes 
thus increasing the tendency of the cells to undergo apoptosis. 
 
• The pharmacological maintenance of intracellular cGMP levels does not only 
contribute to preserved vascular function but does also prevent the otherwise 
unfolding pathologic subcellular changes caused by oxidative damage. Both the 
facilitation of cGMP synthesis by cinaciguat, and the inhibition of cGMP degradation 
by vardenafil efficiently improved the vascular function and hindered the development 
of intracellular pathologic molecular changes. 
 
In the first study we investigated the oxidative injury and impairment of vascular 
responsiveness induced by peroxynitrite in the isolated rat aorta. The second study examined 
the effect of an in vitro ischemia reperfusion injury on the vascular function. In both cases the 
oxidative stress caused vascular dysfunction was associated with decreased cGMP levels 
along with increased apoptosis ratio in the vessel wall. The maintenance of cGMP levels 
through the activation of soluble guanylate cyclase by cinaciguat or through the inhibition of 
phosphodiesterase -5 by vardenafil respectively, led to improved endothelial function and 
decreased DNA damage. These results were coherently supported by the beneficial changes in 
the ratios of pro- and anti-apoptotic factors associated with increased cGMP levels. This work 
includes the study that provided for the first time evidence of the beneficial effect of PDE-5 
inhibition on endothelial protection during cold ischemic storage and reperfusion. 
 Taken together, the current work supports the concept, that pharmacological activation 
of cGMP synthesis and/or inhibition of cGMP decomposition may represent novel potential 
therapy approaches to improve vascular dysfunction associated with oxidative stress. 
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